An Open-Label Feasibility Study to Assess the Safety and Effect of Manualised MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder among Four Australians
Open-label feasibility single-group study (n=4) of MAPS manualised MDMA-assisted psychotherapy for treatment-refractory PTSD with three MDMA-assisted sessions (initial 80 mg; supplemental half-dose at 1.5–2 h; sessions 2–3 may use 80–120 mg).
Details
Open-label feasibility (n=4) assessing delivery of MAPS manualised MDMA-assisted psychotherapy for severe PTSD in Australia; treatment includes three MDMA-assisted sessions plus preparatory and integrative psychotherapy totalling 15 therapy sessions over ~12 weeks.
Each MDMA session is ~8 hours with an initial oral dose (80 mg first session; 80 or 120 mg for later sessions depending on response) and a supplemental half-dose 1.5–2 hours later; therapy delivered by a male/female co-therapy team per MAPS protocol.